Jasper Therapeutics, Inc.
JSPR
$1.65
$0.074.43%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.26M | 5.88M | 5.65M | 5.51M | 5.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.36M | 27.08M | 21.80M | 25.29M | 19.89M |
| Operating Income | -17.36M | -27.08M | -21.80M | -25.29M | -19.89M |
| Income Before Tax | -18.74M | -26.72M | -21.24M | -24.32M | -18.64M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.74M | -26.72M | -21.24M | -24.32M | -18.64M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.74M | -26.72M | -21.24M | -24.32M | -18.64M |
| EBIT | -17.36M | -27.08M | -21.80M | -25.29M | -19.89M |
| EBITDA | -17.13M | -26.82M | -21.52M | -25.04M | -19.35M |
| EPS Basic | -1.13 | -1.74 | -1.41 | -1.62 | -1.24 |
| Normalized Basic EPS | -0.64 | -1.09 | -0.88 | -1.01 | -0.78 |
| EPS Diluted | -1.13 | -1.74 | -1.41 | -1.62 | -1.24 |
| Normalized Diluted EPS | -0.64 | -1.09 | -0.88 | -1.01 | -0.78 |
| Average Basic Shares Outstanding | 16.64M | 15.33M | 15.02M | 15.01M | 15.00M |
| Average Diluted Shares Outstanding | 16.64M | 15.33M | 15.02M | 15.01M | 15.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |